Short- and longer-term all-cause mortality among SARS-CoV-2- infected persons and the pull-forward phenomenon in Qatar
暂无分享,去创建一个
Gheyath K Nasrallah | R. Bertollini | M. Al-Kuwari | H. Yassine | M. Al-Thani | Z. Al-Kanaani | A. Butt | A. Althani | H. Al-Romaihi | A. Jeremijenko | H. Krumholz | A. Latif | H. Chemaitelly | H. Ayoub | P. Tang | M. Hasan | H. Al-Khatib | P. Coyle | E. Al-Kuwari | A. Kaleeckal | R. Shaik | H. Abdul-Rahim | L. Abu-Raddad | A. Al-khal | L. Abu‐Raddad | J. Faust
[1] Gheyath K Nasrallah,et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections , 2022, The New England journal of medicine.
[2] Z. Al-Aly,et al. Long COVID after breakthrough SARS-CoV-2 infection , 2022, Nature Medicine.
[3] Gheyath K Nasrallah,et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar , 2022, Nature Communications.
[4] Gheyath K Nasrallah,et al. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar , 2022, The New England journal of medicine.
[5] Gheyath K Nasrallah,et al. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection , 2022, The New England journal of medicine.
[6] L. Abu-Raddad,et al. Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar , 2022, The New England journal of medicine.
[7] Gheyath K Nasrallah,et al. Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.
[8] L. Abu-Raddad,et al. Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant , 2021, The New England journal of medicine.
[9] M. Hernán,et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study , 2021, The Lancet.
[10] L. Abu-Raddad,et al. SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar , 2021, Scientific Reports.
[11] J. Klausner,et al. A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection , 2021, medRxiv.
[12] L. Abu-Raddad,et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.
[13] Dmitri A. Jdanov,et al. Excess deaths associated with covid-19 pandemic in 2020: age and sex disaggregated time series analysis in 29 high income countries , 2021, BMJ.
[14] Gheyath K Nasrallah,et al. SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar , 2021, Open forum infectious diseases.
[15] L. Abu-Raddad,et al. Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar , 2021, Emerging infectious diseases.
[16] Gheyath K Nasrallah,et al. SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals , 2021, iScience.
[17] R. Bertollini,et al. Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19 , 2020, medRxiv.
[18] R. Bertollini,et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic , 2020, Scientific Reports.
[19] Peter C. Austin,et al. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research , 2009, Commun. Stat. Simul. Comput..
[20] M. Weijenberg,et al. The impact of heat waves and cold spells on mortality rates in the Dutch population. , 2001, Environmental health perspectives.